Format

Send to

Choose Destination
Clin Case Rep. 2018 Mar 13;6(5):875-877. doi: 10.1002/ccr3.1471. eCollection 2018 May.

Hyperbilirubinemia following lenalidomide administration.

Author information

1
Yale University School of Medicine New Haven CT 06510.
2
Yale University School of Medicine Smilow Cancer Hospital, New Haven CT 06510.

Abstract

Asymptomatic hyperbilirubinemia in a patient with no underlying liver disease or renal impairment while on lenalidomide therapy may be attributable to the unmasking of previously undiagnosed Gilbert's syndrome, as previously shown in the literature. The hyperbilirubinemia should resolve after discontinuation of the drug.

KEYWORDS:

Gilbert's syndrome; chemotherapy; hyperbilirubinemia; lenalidomide; multiple myeloma

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center